1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Integrated germline and somatic analysis identifies actionable cancer predisposing germline mutations in 9,734 patients with advanced cancers
    Meeting Abstract

    Jayakumaran, G.; Mandelker, D.; Birsoy, O.; Jairam, S.; Li, Y.; Yang, C.; Somar, J.; Rai, V.; Syed, A.; Benayed, R.; more...
    Journal of Molecular Diagnostics (2019)

    Fulltext@MSK | Save
  • A multicenter, open-label, exploratory platform study to evaluate biomarkers and immunotherapy combinations for the treatment of patients with metastatic castration-resistant prostate cancer (PORTER)
    Meeting Abstract

    Nissola, L.; Autio, K.; Bhardwaj, N.; Galsky, M.; Wentzel, K.; Lucey, V.; Selinsky, C.; Perry, C.; Cabanski, C.; Bitton, A.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune checkpoint inhibitor (CPI)
    Meeting Abstract

    Msaouel, P.; Siefker-Radtke, A.; Sweis, R.; Mortazavi, A.; Vogelzang, N.; Vaishampayan, U.; Bradley, T.; Bupathi, M.; Nordquist, L.; Shaffer, D.; more...
    Journal for ImmunoTherapy of Cancer (2019)

    Fulltext@MSK | Save
  • Phase 2 study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) for disease progression after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M.; Shaffer, D.; Hseih, J. J.; Cohn, A. L.; Di Simone, C.; Marin, A. P.; Rasco, D.; more...
    Asia-Pacific Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC)
    Meeting Abstract

    Motzer, R. J.; Lee, C. H.; Emamekhoo, H.; Matrana, M.; Percent, I.; Hsieh, J. J.; Hussain, A.; Vaishampayan, U. N.; Graham, R.; Liu, S.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD)
    Meeting Abstract

    Smith, M. R.; Sandhu, S. K.; Kelly, W. K.; Scher, H. I.; Efstathiou, E.; Lara, P. N.; Yu, E. Y.; George, D. J.; Chi, K. N.; Saad, F.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma (mccRCC): Results of an interim analysis
    Meeting Abstract

    Lee, C. H.; Shah, A. Y.; Makker, V.; Taylor, M. H.; Shaffer, D.; Hsieh, J. J.; Cohn, A. L.; DiSimone, C.; Pinto Marin, A.; Rasco, D. W.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator's choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)
    Meeting Abstract

    Necchi, A.; Fradet, Y.; Bellmunt, J.; de Wit, R.; Lee, J. L.; Fong, L.; Vozelgang, N. J.; Climent, M. A.; Petrylak, D. P.; Choueiri, T. K.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
    Meeting Abstract

    Hoffman-Censits, J.; Rosenberg, J. E.; van Der Heijden, M.; Dreicer, R.; Perez Gracia, J. L.; Petrylak, D. P.; Retz, M. M.; Sabbatini, R.; Naglieri, E.; Caserta, C.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • Association between depth of response and overall survival: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214
    Meeting Abstract

    Grünwald, V.; Choueiri, T. K.; Rini, B. I.; Powles, T.; George, S.; Grimm, M. O.; McHenry, M. B.; Maurer, M.; Motzer, R. J.; Hammers, H. J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save